Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 95.08M P/E - EPS this Y -57.10% Ern Qtrly Grth -
Income -53.73M Forward P/E -1.95 EPS next Y -17.60% 50D Avg Chg -14.00%
Sales 9.28M PEG -0.12 EPS past 5Y - 200D Avg Chg -4.00%
Dividend N/A Price/Book 0.78 EPS next 5Y 10.90% 52W High Chg -64.00%
Recommedations 1.30 Quick Ratio 11.87 Shares Outstanding 43.70M 52W Low Chg 92.00%
Insider Own 6.23% ROA -21.51% Shares Float 24.76M Beta 0.46
Inst Own 74.24% ROE -48.27% Shares Shorted/Prior 1.12M/1.06M Price 2.67
Gross Margin - Profit Margin - Avg. Volume 42,648 Target Price 12.00
Oper. Margin -1,658.79% Earnings Date - Volume 34,748 Change -2.55%
About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Werewolf Therapeutics, Inc. News
11/20/24 Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
11/07/24 Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
11/07/24 Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
10/31/24 Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
10/20/24 Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks
10/04/24 Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
09/03/24 Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
08/10/24 Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/08/24 Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
08/08/24 Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
06/25/24 Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
06/01/24 Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
05/30/24 Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
05/23/24 Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
05/03/24 Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
04/24/24 Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04/23/24 Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
04/15/24 All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
04/05/24 Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
04/04/24 Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
HOWL Chatroom

User Image stockymcstockface3 Posted - 6 hours ago

$HOWL wow green?! Thats a color I havent seen in a long time on this. Lets see if it sticks or keeps dropping…

User Image BMK00 Posted - 1 day ago

$HOWL Would love to add more in the 1.60’s

User Image west281356 Posted - 2 days ago

$HOWL interesting price action in spite of five consecutive quarters of increasing fund ownership….

User Image OldToad77 Posted - 2 days ago

$HOWL Added some pre market HC Wainwright & Company maintains buy, $15 Price Target :)

User Image Don_Heisenberg Posted - 2 days ago

$HOWL this a good entry? Thinking of starting a position. Thanks

User Image BalticAve Posted - 3 days ago

$HOWL Down 42 percent. I've never made a mistake like this

User Image Will2ride1 Posted - 3 days ago

$HOWL take this

User Image First_Class_Seaman Posted - 4 days ago

$HOWL would be a nice idea to swing this. How long will it take? $ZONE Monday we're heading to the bank. SO MUCH BULLISH HERE

User Image Reba12 Posted - 6 days ago

$HOWL i think the same

User Image Dukemandu Posted - 6 days ago

$HOWL BTW, HC Wainwright claimed this would 1 year to $15.... LAST YEAR TO THIS DAY! Look it up.

User Image Dukemandu Posted - 6 days ago

$HOWL Ok. This is starting to piss me off: Close it its all time low of the year. ALL these analysts "reinterring" a buy over and over again at $15 in a year... AS it's collapsing. That last pump even BOA jumped in. Even as the market screamed up, this stock just got hammered down. So, WTF am I seeing? Why don't these guys get sued or investigated by the sec? I see analysts do this shit all the time, but not often with this kind of pigheaded intensity and CONTINUE to be so wrong. What are they doing? Unloading their bags on retail? That would be illegal and multiple analysts are unlikely working in coo hoots to do this.

User Image stockymcstockface3 Posted - 6 days ago

$HOWL oof

User Image BMK00 Posted - 6 days ago

$HOWL Good loading zone here

User Image BalticAve Posted - 6 days ago

$HOWL worst stock I've ever bought. Would love any kind of positivity here

User Image Will2ride1 Posted - 6 days ago

$HOWL starter taken

User Image Bullly Posted - 1 week ago

$HOWL average down? Where's the bottom?

User Image Ssethonayash Posted - 1 week ago

$GNTA $HOWL $BOLT.CN 🚀huge PR incoming, loading up. 🚨 Stock alert shared across 3 Discord groups. The 2-for-1 split is complete. Trader interest is rising, with average volume up from 28k to 81k, and recent spikes hitting 259k - 800k. Something big is brewing!

User Image incom101 Posted - 1 week ago

$HOWL gap is filled earnings beat and good news on trials. Time to flip the switch to more green days then red ones. Imo

User Image incom101 Posted - 1 week ago

$HOWL gap filled finally

User Image Bullly Posted - 1 week ago

$HOWL well. $3 🙏

User Image BMK00 Posted - 1 week ago

$HOWL Almost reloading time…sub $2 adds are a gift for holding this one LT

User Image mjhousto Posted - 1 week ago

$HOWL investors.werewolftx.com/news-releases/news-release-details/werewolf-therapeutics-reports-third-quarter-2024-financial

User Image mjhousto Posted - 1 week ago

$HOWL https://investors.werewolftx.com/node/8426/pdf

User Image Sanjaynaik2011 Posted - 1 week ago

$HOWL These some of SCUMS (Insiders and Hedge Fuc*s) are trying to get this to $1.90s and buy all. So my guess is to wait until that price tag. This will fly. Buy anything under $2. Manipulation is in play!!

User Image andeski Posted - 1 week ago

$HOWL this company still has an average price target of $12 so patience, everything negative is just noise.

User Image Bullly Posted - 2 weeks ago

$HOWL like salt on a slug :(

User Image Biotech_Beast Posted - 2 weeks ago

$MDNAF have to watch $HOWL as well. I hold both, although HOWL has the IL-12 (WTX-330), so both names can find their niche.

User Image Bullly Posted - 2 weeks ago

$HOWL :( $2?

User Image OldToad77 Posted - 2 weeks ago

$HOWL https://www.stocktitan.net/news/HOWL/werewolf-therapeutics-announces-promising-new-development-candidate-7asglqus7xew.html

User Image jacky1230 Posted - 10/31/24

$HOWL 2.59 now

Analyst Ratings
HC Wainwright & Co. Buy Jul 2, 24
JMP Securities Market Outperform Jun 26, 24
HC Wainwright & Co. Buy Jun 26, 24
JMP Securities Market Outperform Jun 4, 24
HC Wainwright & Co. Buy Jun 3, 24
HC Wainwright & Co. Buy May 24, 24
JMP Securities Market Outperform May 6, 24
HC Wainwright & Co. Buy May 6, 24
JMP Securities Market Outperform Apr 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RA CAPITAL MANAGEMENT, L.P. Director Director Jan 06 Buy 2.21 1,853,000 4,095,130 5,701,056 01/10/23
Seidel-Dugan Cynthia Chief Scientific Off.. Chief Scientific Officer Jan 06 Option 3.17 39,731 125,947 164,888 01/14/22